Key result
Obesity and chronic kidney disease share phenotypes in 20% to 30% of individuals, forming a vicious cycle driven by inflammation that increases cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Obesity and chronic kidney disease share a bidirectional relationship driven by chronic inflammation, highlighting the potential role of new medications targeting inflammation and metabolic pathways.
Obesity represents a serious and growing disease worldwide. The pathophysiological changes secondary to chronic inflammation lead to the development of diseases that increase the morbidity and mortality of individuals. Chronic kidney disease (CKD) is a condition with deleterious effects that acts bidirectionally with obesity. From approximately 20% to 30% of individuals share phenotypes of CKD and obesity, increasing their cardiovascular risk and the risk of other complications. Obesity and CKD form a vicious cycle in which inflammation is the central axis of multiorgan damage. Despite increasing the risk of cardiac and renal mortality, CKD progresses in relation to body mass index and albuminuria. Nowadays, the implementation of the new medications aimed at mitigating the peak of inflammation is becoming a cornerstone of treatments for obesity, diabetes, cardiovascular diseases, and renal disease.
No takes yet. Share an insight, caveat, or question.
León-Román et al. (2025) conducted a review in Obesity and Chronic Kidney Disease. Obesity was evaluated. Obesity and chronic kidney disease share phenotypes in 20% to 30% of individuals, forming a vicious cycle driven by inflammation that increases cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: